Immune Environment and Osteosarcoma

Immune niche with its huge cell diversity including more specifically tumour infiltrating lymphocytes (TILs), tumour-associated macrophages (TAMs) regulate osteosarcoma (OS) microenvironment. TAMs exert differential activities in the tumour development according to their polarisation. Indeed, in oncology, M1-polarised macrophages are considered as anti-tumour effectors, and M2-polarised macrophages are defined as pro-tumour modulators by increasing the neoangiogenic process. TAM density is correlated with tumour cell proliferation, invasion, metastasis and poor prognosis in various epithelial and haematological cancers and in bone metastasis. Similarly, tumour infiltrating lymphocytes play a key role in tumour development by inducing a local tolerant environment favourable for the tumour growth. The present chapter will describe the main roles of the immune system in the pathogenesis of osteosarcoma and the most recent therapeutic development based on its regulation.

[1]  M. Heymann,et al.  Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.

[2]  M. Heymann,et al.  RANK–RANKL signalling in cancer , 2016, Bioscience reports.

[3]  N. Matsumura,et al.  PD-1/PD-L1 blockade in cancer treatment: perspectives and issues , 2016, International Journal of Clinical Oncology.

[4]  D. Heymann,et al.  L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. , 2016, American journal of cancer research.

[5]  C. Gomes,et al.  Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. , 2016, Translational research : the journal of laboratory and clinical medicine.

[6]  S. Aiba,et al.  The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages. , 2015, The Journal of investigative dermatology.

[7]  S. Roberts,et al.  Immunotherapy of Childhood Sarcomas , 2015, Front. Oncol..

[8]  D. Heymann,et al.  Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment , 2015, International journal of cancer.

[9]  L. Diller,et al.  A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma , 2015, Cancer Immunology, Immunotherapy.

[10]  S. Aiba,et al.  Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Promotes the Production of CCL17 from RANK|[plus]| M2 Macrophages , 2015 .

[11]  E. Álava,et al.  Bone microenvironment signals in osteosarcoma development , 2015, Cellular and Molecular Life Sciences.

[12]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[13]  A. L. Bosch,et al.  CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study , 2015, Oncoimmunology.

[14]  A. Goldhirsch,et al.  Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. , 2015, Cancer treatment reviews.

[15]  Yue Zhou,et al.  Expression of programmed death 1 is correlated with progression of osteosarcoma , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[16]  P. Ordóñez-Morán,et al.  Complex metastatic niches: already a target for therapy? , 2014, Current opinion in cell biology.

[17]  P. De Baetselier,et al.  Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression , 2014, Front. Immunol..

[18]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Z. Duan,et al.  Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential , 2014, Oncoimmunology.

[20]  M. De la Fuente,et al.  Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.

[21]  Yu Yang,et al.  Inhibition of macrophage polarization prohibits growth of human osteosarcoma , 2014, Tumor Biology.

[22]  Mark S. Anderson,et al.  Brief Definitive Report , 2022 .

[23]  M. Schilham,et al.  Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.

[24]  R. Gorlick,et al.  Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma , 2014, Cancer.

[25]  Klaus Pantel,et al.  Tumor metastasis: moving new biological insights into the clinic , 2013, Nature Medicine.

[26]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[27]  T. Hagemann,et al.  Tumour-associated macrophages and cancer. , 2013, Current opinion in pharmacology.

[28]  D. Hughes,et al.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression , 2013, Front. Oncol..

[29]  S. Lessnick,et al.  Children's Oncology Group's 2013 blueprint for research: Bone tumors , 2013, Pediatric blood & cancer.

[30]  M. Heymann,et al.  Current Therapeutic Strategies and Novel Approaches in Osteosarcoma , 2013, Cancers.

[31]  T. He,et al.  The Current and Future Therapies for Human Osteosarcoma. , 2013, Current cancer therapy reviews.

[32]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[33]  A. Evdokiou,et al.  The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. , 2012, Biochimica et biophysica acta.

[34]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[35]  I. Ostrovnaya,et al.  Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Mueller,et al.  Emerging Functions of RANKL in Lymphoid Tissues , 2012, Front. Immun..

[37]  Kathryn L. Parsley,et al.  Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma , 2012, Clinical and Translational Oncology.

[38]  I. Holen,et al.  Tumour macrophages as potential targets of bisphosphonates , 2011, Journal of Translational Medicine.

[39]  Anne-Marie Cleton-Jansen,et al.  Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents , 2011, Clinical Cancer Research.

[40]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[41]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Picci,et al.  Palliative therapy for osteosarcoma , 2011, Expert review of anticancer therapy.

[43]  T. Dønnem,et al.  Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas , 2011, PloS one.

[44]  D. Heymann,et al.  Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.

[45]  D. Heymann.  Interleukin-34: An enigmatic cytokine , 2010 .

[46]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[47]  E. Kleinerman,et al.  Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group , 2010, Clinical Cancer Research.

[48]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[49]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[50]  S. Bielack,et al.  The role of radiotherapy in oseosarcoma. , 2009, Cancer treatment and research.

[51]  T. Suda,et al.  Cancer stem cells and their niche , 2009, Cancer science.

[52]  G. Basak,et al.  Multiple myeloma bone marrow niche. , 2009, Current pharmaceutical biotechnology.

[53]  B. Trinité,et al.  Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. , 2008, Cancer research.

[54]  H. Takayanagi,et al.  The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. , 2008, Immunity.

[55]  L. Williams,et al.  Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome , 2008, Science.

[56]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[58]  E. Horwitz,et al.  Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. , 2007, Blood.

[59]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[60]  D. Heymann,et al.  Osteosarcoma: current status of immunotherapy and future trends (Review). , 2006, Oncology reports.

[61]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[62]  Piero Picci,et al.  Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. , 2005, European journal of cancer.

[63]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[64]  S. Théoleyre,et al.  Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma , 2005, BMC Cancer.

[65]  R. Rezzonico,et al.  The receptor activator of nuclear factor (NF)κB ligand (RANKL) is a new chemotactic factor for human monocytes , 2003 .

[66]  S. Gordon,et al.  Monocyte heterogeneity and innate immunity. , 2003, Immunity.

[67]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[68]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[69]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[70]  K. Hirokawa,et al.  Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus. , 2001, Endocrinology.

[71]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[72]  S. Larson,et al.  3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. , 1998, International journal of oncology.

[73]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[75]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[76]  J. Månsson,et al.  Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.

[77]  N. Cheung,et al.  Disialoganglioside GD2 anti‐idiotypic monoclonal antibodies , 1993, International journal of cancer.

[78]  E. Kleinerman,et al.  Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  P. Hersey,et al.  Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma , 1988, International journal of cancer.

[80]  N. Cheung,et al.  Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. , 1987, Cancer research.

[81]  N. Berger,et al.  Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  G. Rosen,et al.  The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma , 1975, Cancer.

[83]  R. van Furth,et al.  THE ORIGIN AND KINETICS OF MONONUCLEAR PHAGOCYTES , 1968, The Journal of experimental medicine.

[84]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[85]  S. Gottschalk,et al.  Genetically modified T-cell therapy for osteosarcoma. , 2014, Advances in experimental medicine and biology.

[86]  Dean Anthony Lee,et al.  Natural killer cells for osteosarcoma. , 2014, Advances in experimental medicine and biology.

[87]  Zhaoxu Li.  Potential of human γδ T cells for immunotherapy of osteosarcoma , 2012, Molecular Biology Reports.

[88]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[89]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[90]  K. Hirokawa,et al.  Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. , 2001, Endocrinology.

[91]  K. Trieb,et al.  Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. , 1998, Pathology, research and practice.